🎉 M&A multiples are live!
Check it out!

Neumora Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Neumora Therapeutics and similar public comparables like Pharming, Vivoryon Therapeutics, and Benevolent AI.

Neumora Therapeutics Overview

About Neumora Therapeutics

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.


Founded

2019

HQ

United States of America
Employees

110

Website

neumoratx.com

Financials

LTM Revenue n/a

LTM EBITDA -$269M

EV

-$197M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Neumora Therapeutics Financials

Neumora Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$269M.

In the most recent fiscal year, Neumora Therapeutics achieved revenue of n/a and an EBITDA of -$263M.

Neumora Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Neumora Therapeutics valuation multiples based on analyst estimates

Neumora Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$251M -$263M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$131M -$236M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Neumora Therapeutics Stock Performance

As of April 15, 2025, Neumora Therapeutics's stock price is $1.

Neumora Therapeutics has current market cap of $108M, and EV of -$197M.

See Neumora Therapeutics trading valuation data

Neumora Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$197M $108M XXX XXX XXX XXX $-1.51

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Neumora Therapeutics Valuation Multiples

As of April 15, 2025, Neumora Therapeutics has market cap of $108M and EV of -$197M.

Neumora Therapeutics's trades at n/a LTM EV/Revenue multiple, and 0.7x LTM EBITDA.

Analysts estimate Neumora Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Neumora Therapeutics and 10K+ public comps

Neumora Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$197M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.8x XXX XXX XXX
P/E -0.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Neumora Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Neumora Therapeutics Valuation Multiples

Neumora Therapeutics's NTM/LTM revenue growth is Infinity%

Neumora Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.4M for the same period.

Over next 12 months, Neumora Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Neumora Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Neumora Therapeutics and other 10K+ public comps

Neumora Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 5% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Neumora Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Neumora Therapeutics M&A and Investment Activity

Neumora Therapeutics acquired  XXX companies to date.

Last acquisition by Neumora Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Neumora Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Neumora Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Neumora Therapeutics

When was Neumora Therapeutics founded? Neumora Therapeutics was founded in 2019.
Where is Neumora Therapeutics headquartered? Neumora Therapeutics is headquartered in United States of America.
How many employees does Neumora Therapeutics have? As of today, Neumora Therapeutics has 110 employees.
Who is the CEO of Neumora Therapeutics? Neumora Therapeutics's CEO is Mr. Paul L. Berns.
Is Neumora Therapeutics publicy listed? Yes, Neumora Therapeutics is a public company listed on NAS.
What is the stock symbol of Neumora Therapeutics? Neumora Therapeutics trades under NMRA ticker.
When did Neumora Therapeutics go public? Neumora Therapeutics went public in 2023.
Who are competitors of Neumora Therapeutics? Similar companies to Neumora Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Neumora Therapeutics? Neumora Therapeutics's current market cap is $108M
What is the current EBITDA of Neumora Therapeutics? Neumora Therapeutics's last 12-month EBITDA is -$269M.
What is the current EV/EBITDA multiple of Neumora Therapeutics? Current EBITDA multiple of Neumora Therapeutics is 0.7x.
Is Neumora Therapeutics profitable? Yes, Neumora Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.